MGNX earnings call for the period ending September 30, 2021.
Compare MGNX Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: MacroGenics
Investors weren't thrilled with the company's latest clinical data.
Investors are signaling hope in the company's top drug, despite a disappointing final analysis.
MGNX earnings call for the period ending June 30, 2021.
The company provided its Q2 update.
The company announced preliminary phase 1 results for its tumor-fighting drug MGC018.
MGNX earnings call for the period ending March 31, 2021.
MGNX earnings call for the period ending December 31, 2020.
The company published data from a late-stage study of its promising breast cancer drug.
There were different reactions to the company's first FDA approval.